Anti-inflammatory drugs like Vioxx, which is being pulled off the market after it was linked to cardiac problems, could pose similar riskald of the University of Pennsylvania, who led one of the studies funded by the two pharmaceutical firms.
Last week, a consumer group in Quebec filed suit against Merck, charging that it kept Vioxx on the market despite the risks.
The number of users outside the United States was "undetermined."
The additional, more serious step taken Monday reflects the momentum in the Vioxx litigation and the delay in launching Arcoxia, Vioxx's successor drugs, said S&P analyst Arthur Wong.
